E-Therapeutics News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.10.24	e-therapeutics Announces Business Updates and Interim Results (GlobeNewswire)
16.07.24	e-therapeutics plc, Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors (EQS Group)
03.07.24	e-therapeutics announces completion of £28.90 million fundraise (EQS Group)
23.05.24	Lord David Prior Appointed as Chair of e-therapeutics’ Board of Directors (EQS Group)
09.05.24	e-therapeutics plc shares now trading on JP Jenkins (EQS Group)
13.11.23	Edison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery (EQS Group)
30.09.22	e-therapeutics: Fundraise of £13.5 million (PR Newswire)
05.03.19	Edison issues update on e-Therapeutics (ETX) (EQS Group)
12.12.18	Edison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX) (EQS Group)
06.12.18	Edison Investment Research Limited: Edison issues update on e-Therapeutics (ETX) (EQS Group)
08.10.18	Edison issues update on e-Therapeutics (ETX) (EQS Group)
27.03.18	e-therapeutics plc: Full Year Results (Businesswire)
27.07.17	EQS-News: E-Therapeutics PLC (EQS Group)
24.07.17	e-Therapeutics Announces Outcome of Strategic Review and Future Plans (Businesswire)
29.09.15	e-Therapeutics: Discovery Platform Exceeding Expectations; Company Focus Now on Commercialisation (Businesswire)
31.03.15	e-Therapeutics plc Announces Full Year Results (Businesswire)
16.09.14	Four Clinical Trials in Progress; New Drug Candidates in Laboratory Testing (Businesswire)
12.05.14	e-Therapeutics’ Full Year Results for the 12 Months Ended 31 January 2014 (Businesswire)
08.05.14	e-Therapeutics announces recruitment resumes into US phase I ETS2101 brain cancer trial (Businesswire)
31.03.14	e-Therapeutics reports positive interim results from UK phase Ia trial of ETS2101 (dexanabinol) in a variety of solid tumours (Businesswire)
26.03.14	e-Therapeutics announces recruitment resumes into UK phase I ETS2101 cancer trial (Businesswire)
10.02.14	e-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers (Businesswire)
24.01.14	e-Therapeutics Announces Temporary Halt of Recruitment into ETS2101 Cancer Trials Because of Drug Supply Issue (Businesswire)
07.01.14	e-Therapeutics provides update on ETS2101 phase I trial in brain cancer (Businesswire)
16.10.13	e-Therapeutics' Interim Results for the Six Months Ended 31 July 2013 (Businesswire)
18.12.12	e-Therapeutics provides update on progress of ETS2101 cancer trials (Businesswire)
22.10.12	e-Therapeutics plc ("e-Therapeutics" or the "Company") - Interim Results for the Six Months Ended 31 July 2012 (Businesswire)
12.09.12	e-Therapeutics Starts Second Phase I Cancer Trial of ETS2101 (Businesswire)
19.06.12	e-Therapeutics' ETS2101 enters phase I clinical trial in brain cancer (Businesswire)
22.05.12	e-Therapeutics’ Preliminary Results for the Year Ended 31 January 2012 (Businesswire)
29.03.12	e-Therapeutics' Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators (Businesswire)
26.02.12	Prime Minister Opens e-Therapeutics’ Drug Discovery Centre Near Oxford (Businesswire)
08.02.12	e-Therapeutics to Present at The 14th Annual BIO CEO & Investor Conference (Businesswire)
06.02.12	Celgene Executive Dr Rajesh Chopra Joins the Board of e-Therapeutics (Businesswire)
09.01.12	e-Therapeutics Outlines Goals for 2012 and Announces Presentation at Biotech Showcase Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.94	2.23 %	K V
CieFinRichemont	123.00	1.53 %	K V
Lonza Grp	531.00	0.84 %	K V
Logitech Intl	72.62	0.58 %	K V
Part Grp Hldg	1’265.00	0.36 %	K V
Geberit	523.00	-0.61 %	K V
Swisscom	505.50	-0.69 %	K V
ABB	49.55	-0.82 %	K V
Holcim	88.84	-1.05 %	K V
UBS Group	27.74	-2.15 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu E-Therapeutics PLC

Aktien Top/Flop

Meistgelesene Nachrichten